How can drug discovery for psychiatric disorders be improved?

Yves Agid, György Buzsáki, David M. Diamond, Richard Frackowiak, Jay Giedd, Jean Antoine Girault, Anthony Grace, Jeremy J. Lambert, Husseini Manji, Helen Mayberg, Maurizio Popoli, Alain Prochiantz, Gal Richter-Levin, Peter Somogyi, Michael Spedding, Per Svenningsson, Daniel Weinberger

Research output: Contribution to journalReview articlepeer-review


Psychiatric disorders such as depression, anxiety and schizophrenia are leading causes of disability worldwide, and have a huge societal impact. However, despite the clear need for better therapies, and major advances in the understanding of the molecular basis of these disorders in recent years, efforts to discover and develop new drugs for neuropsychiatric disorders, particularly those that might revolutionize disease treatment, have been relatively unsuccessful. A multidisciplinary approach will be crucial in addressing this problem, and in the first Advances in Neuroscience for Medical Innovation symposium, experts in multiple areas of neuroscience considered key questions in the field, in particular those related to the importance of neuronal plasticity. The discussions were used as a basis to propose steps that can be taken to improve the effectiveness of drug discovery for psychiatric disorders.

Original languageEnglish
Pages (from-to)189-201
Number of pages13
JournalNature Reviews Drug Discovery
Issue number3
StatePublished - Mar 2007

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology


Dive into the research topics of 'How can drug discovery for psychiatric disorders be improved?'. Together they form a unique fingerprint.

Cite this